Aug 4, 2026 08:30AM
Aug 4, 2026 08:30AM
Aug 3, 2026 08:30AM
Jul 30, 2026 08:30AM
Jul 27, 2026 08:10AM
Jul 27, 2026 08:10AM
Jul 7, 2026 08:30AM Veru to Present at 2026 Obesity & Weight Loss Drug Development Summit and Pre-Conference Workshop Day
May 13, 2026 06:30AM
May 13, 2026 06:30AM
May 6, 2026 08:30AM
Mar 9, 2026 08:31AM
Mar 9, 2026 08:30AM
Feb 19, 2026 08:30AM
Feb 11, 2026 06:30AM Veru Reports Fiscal 2026 First Quarter Financial Results and Clinical Program Progress
Feb 4, 2026 08:30AM
Dec 18, 2025 04:14AM
Dec 17, 2025 06:31AM
Dec 17, 2025 06:30AM
Dec 10, 2025 08:30AM
Dec 4, 2025 08:30AM
Oct 31, 2025 08:30AM Veru to Present Two Abstracts at ObesityWeek 2025
Sep 23, 2025 08:30AM
Sep 23, 2025 08:30AM
Aug 13, 2025 02:39PM
Aug 13, 2025 05:30AM
Aug 12, 2025 06:30AM
Aug 11, 2025 04:01PM
Aug 11, 2025 04:01PM Laxxon Medical Announces Successful Product Development Milestone with Novel Oral Modified-Release Formulation of Veru’s Enobosarm, Utilizing Laxxon’s SPID®-Technology
Aug 11, 2025 08:30AM
Aug 11, 2025 08:30AM
Aug 6, 2025 08:30AM
Aug 6, 2025 08:30AM
Aug 5, 2025 08:30AM
Jul 22, 2025 08:30AM
Jun 24, 2025 08:30AM Veru, Inc. (VERU) Reports Positive Results from Phase 2b QUALITY and Maintenance Extension Study
Jun 24, 2025 08:30AM
Jun 11, 2025 08:30AM
May 28, 2025 06:33AM
May 28, 2025 06:30AM
May 8, 2025 09:25AM
May 8, 2025 06:30AM
May 1, 2025 08:30AM Veru to Report Fiscal 2025 Second Quarter Financial Results on May 8
Apr 16, 2025 08:30AM
Mar 31, 2025 08:30AM
Feb 13, 2025 06:30AM
Feb 6, 2025 08:30AM
Feb 4, 2025 08:30AM
Jan 27, 2025 06:30AM
Jan 27, 2025 06:30AM Veru Announces Positive Topline Data from Phase 2b QUALITY Clinical Study: Enobosarm Preserved Lean Mass in Patients Receiving WEGOVY® (Semaglutide) for Weight Reduction
Jan 24, 2025 09:07AM

327,669 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All